Therapeutic effects of angiotensin (AT1) receptor antagonists: Potential contribution of mechanisms other than AT1 receptor blockade

American Journal of Cardiovascular Drugs

Volumn 4, Issue 6, 2004, Pages 361-368

  Schmidt, Boris ^a   Drexler, Helmut ^b   Schieffer, Bernhard ^b,c  

^a DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CAPTOPRIL; CIMETIDINE; CYCLIC AMP PHOSPHODIESTERASE; CYTOCHROME P450; DIAZEPAM; ENALAPRIL; EPROSARTAN; FLUCONAZOLE; IBUPROFEN; INDOMETACIN; IRBESARTAN; LISINOPRIL; LOSARTAN; NAPROXEN; OLMESARTAN; PHENOBARBITAL; PROSTAGLANDIN SYNTHASE; QUINAPRIL; RAMIPRIL; RECOMBINANT GROWTH HORMONE; TASOSARTAN; TELMISARTAN; UNINDEXED DRUG; VALSARTAN; WARFARIN;

AREA UNDER THE CURVE; BINDING AFFINITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS; RENIN-ANGIOTENSIN SYSTEM;

EID: 10444283441     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404060-00004     Document Type: Review

References (17)

1. Levine B, Kalman J, Mayer L, et al. Elevated circulating tumor necrosis factor in patients with severe chronic heart failure. N Engl J Med 1990; 323: 236-41
2. Stearns RA, Miller RR, Doss GA, et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 1992; 20: 281-7
3. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26: 408-17
4. Prendergast K, Adams K, Greenlee WJ, et al. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor. J Comput Aided Mol Des 1994; 8: 491-512
5. Noda K, Saad Y, Kinoshita A, et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270: 2284-9
6. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15 Suppl. F: 26F-8F
7. Cox P, Bush B, Gorycki P. The metabolic fate of eprosartan in healthy volunteers. Exp Toxicol Pathol 1996; 48: 5
8. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-20
9. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610-8
10. Kaukonen K-M, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445-9
11. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 417-25
12. Waldmeier F, Flesch G, Müller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single dose. Xenobiotica 1997; 27: 59-71
13. Schieffer B, Schmidt B. Angiotensin II AT1 receptor antagonists: clinical implications of active metabolites. J Med Chem 2003; 46 (12): 2261-70
14. Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-6
15. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997; 281: 1065-70
16. Liu EC, Hedberg A, Goldenberg HG, et al. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1992; 44: 89-99
17. Ueyama T, Ohkusa T, Yano M, et al. Growth hormone preserves cardiac sarcoplasmic reticulum Ca2+ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc Res 1998; 40: 64-73